

FINAL EXAM  
DECEMBER 2016

NATIONAL BOARD OF EXAMINATIONS

**MEDICAL ONCOLOGY**

PAPER – III

MED.ONCO/D/16/17/III

Time : 3 hours

Max. Marks : 100

**Important instructions:**

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. Combined modality management of a 60 year old male with Stage III adenocarcinoma of lung: 1+4+2+2+1
  - a) Factors deciding treatment plan.
  - b) Concurrent chemoradiation dosages.
  - c) Induction chemotherapy with radiation.
  - d) Role of surgery in stage III NSCLC.
  - e) Follow-up plan.
2. PARP inhibitors: 3+2+2+3
  - a) Principles and role of PARP in DNA repair.
  - b) Name PARP inhibitors.
  - c) Indications
  - d) Complications of their usage.
3.
  - a) Define tumor microenvironment. 2+4+4
  - b) How this information is now being used in the treatment of chronic lymphocytic leukemia (CLL).
  - c) Give briefly pharmacology of newer oral drugs being used in treatment of chronic lymphocytic leukemia.
4. Cyberknife: 5+3+2
  - a) Principles
  - b) Indications
  - c) Limitations/complications
5. Hospice care: 1+3+3+3
  - a) Definition.
  - b) Elements of Hospice care.
  - c) Counseling strategies for patients and relatives.
  - d) Status of hospice care in India.

**P.T.O.**

FINAL EXAM  
DECEMBER 2016

NATIONAL BOARD OF EXAMINATIONS

**MEDICAL ONCOLOGY**  
**PAPER – III**

6. Out-patient management of febrile neutropenia : 2+2+2+2+2  
a) Assessment of risk of complications.  
b) Antibiotic usage in an out-patient setting.  
c) Use of G-CSF – Regular vs PEG G-CSF.  
d) Monitoring patient in an out-patient setting.  
e) Indications for admission as in-patients.
7. Hormonal management of prostatic cancer: 4+2+4  
a) Various hormonal agents.  
b) Various screening methods for prostatic cancer.  
c) Management of hormone resistant skeletal metastasis.
8. Cancers with viral etiology: 3+3+4  
a) List the viruses and related cancers.  
b) Treatment of HCV infection.  
c) How will you confirm that the given tumour is due to viral infection?
9. Management of malignant pleural effusion/treatment of haemorrhagic pleural effusion/selection criteria for ICD: 2+4+2+2  
a) Lab investigations.  
b) How to exclude inflammatory and other non-malignant causes of pleural effusion?  
c) Selection of patients for ICD.  
d) Pleural cavity interventions.
10. Monoclonal Gammopathy of Undetermined Significance (MGUS): 2+2+3+3  
a) Definition.  
b) Prognostic factors.  
c) Initial treatment regimens and maintenance therapy.  
d) Allogenic BMT and treatment of relapsed disease.

\*\*\*\*\*